Clinical trial · Observational
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
Liver Metastasis of Pancreatic Cancer：Chinese Surgical Study Group
NCT06873178CI-TRIAL-00088624PCLM:CSSGunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the clinical characteristics of pancreatic cancer patients with liver metastases who can benefit from surgery, and to develop evaluation criteria for surgical indications, so as to provide basis for comprehensive treatment strategies for advanced pancreatic cancer patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adjuvant Therapy | — | UNRESOLVED | — |
| Liver Metastases | Pancreatic Neoplasm | PROBABILISTIC | 0.70 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- retrospective
- description
- Retrospectively collect cases of pancreatic cancer with synchronous liver metastasis treated and analyze the preliminary results.
- label
- foresight
- description
- On the basis of retrospective studies, a prospective clinical study is conducted. Through the prospective study of the outcomes of systemic treatment for patients with pancreatic cancer liver metastasis and the clinical results of surgical treatment after the effectiveness of systemic treatment, a basis is provided for the diagnosis and treatment strategies of pancreatic cancer liver metastasis.
Primary outcomes (1)
- measure
- OS
- timeFrame
- through study completion, an average of 2 year
- description
- Overall Survival
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-75 years old * Pancreatic cancer was diagnosed as pancreatic ductal adenocarcinoma by biopsy of primary/metastases * Physical Condition Score (ECOG)0-1 * Simultaneous/prior discovery of liver metastases and primary lesions was defined as simultaneous liver metastases * Enhanced CT/MRI can detect liver metastases (if the diseases not detected by enhanced CT/MRI during screening are not included in the number calculation) * The patient's liver, kidney and bone marrow function is good Exclusion Criteria: * The primary lesions of pancreatic cancer are acinar cell carcinoma of pancreas, neuroendocrine carcinoma of pancreas and other pathological types * there are other metastases outside the liver * Had other malignant tumors within 5 years * History of central nervous system disease, mental illness, unstable angina pectoris, congestive heart failure, severe arrhythmia and other serious diseases * Active or chronic hepatitis B/C virus infection * Allergy to iodine, unable to perform enhanced imaging * Previous anti-tumor therapy for pancreatic cancer (surgery/ radiotherapy/ chemotherapy/ ablation/ targeted therapy/ immunotherapy)
References
Publications (0)
Data not yet available
No reference posted for this study.